From Dean Rewerts, Action Chair
This bill will enact some modest reporting requirements on health care providers and insurers on how drug costs affect their costs, fees and/or premiums; and how they relate to premiums. Some of this information will be made available in a public report.
Failure to comply with the first provision could result in criminal penalties. Failure to comply with the second provision could result in civil penalties.
It would also require drug manufacturers to notify the Office of Statewide Health Planning and Development (OSHPD) 90 days prior to wholesale price increases. This information will be available on OSHPD’s website.
SB17 has passed the Senate and is on its way to the Assembly. We will monitor and keep you informed of the progress and any action needed by you.